Pfizer, pocketing a big tax cut from Trump, ends investment in Alzheimer's and Parkinson's research.

With every passing day, it becomes clearer who's reaping the benefit of the huge tax cut handed over to American corporations by the Republican-dominated Congress in December. The big drug company Pfizer seems intent on being a pace-setter in cranking out the benefits of the tax cut to stakeholders who need them the least. In an announcement in late January, Pfizer said it was shutting down its research efforts on treatments for Alzheimer's and Parkinsonism. The company didn't say how much it was spending on the two conditions, but said about 300 researchers will lose their jobs as it redirects its research and development budget elsewhere. Healthcare In America's Donna Smith talks about what this means to those who count on continued research.